Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combined Treatment With Reboxetine and Methylphenidate in Adults With PTSD
NCT05133804Phase 2Recruiting
- Sponsor
- University of Haifa
- Start
- Jun 2022
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of reboxetine, methylphenidate hydrochloride extended-release chewable tablet in post-traumatic stress disorder (PTSD), sponsored by University of Haifa. Started Jun 2022; status: recruiting.
02
Drugs
reboxetinemethylphenidate hydrochloride extended-release chewable tablet
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT05133804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05133804.